BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Oct 29, 2007
 |  BioCentury  |  Finance

EPS watch

EPS watch

Company 3Q07 EPS est 3Q07 EPS actual Outcome Growth from 3Q06 10/26 cls Wk chg % chg Mcap chg 10/26 Mcap
Affymetrix (AFFX) $0.06 $0.12 Beat by $0.06 NA $25.73 -$1.61 -6% -$110.1 $1,758.8
The microarray company posted a loss per share of $0.06 in 3Q06. Second quarter revenues were up 12% to $95M from $84.7M in 2Q06.
Amgen (AMGN) $1.03 $1.08 Beat by $0.05 4% $57.18 $1.23 2% $1,335.8 $62,097.5
3Q07 revenues were flat at $3.6B, while sales edged up 1% to $3.52B from $3.5B in 3Q06. The 2007 sales also reflect a positive foreign currency impact. 3Q07 sales of Aranesp for anemia were $818M, down 23% from $1.07B in 3Q06 and off by 14% from $949M in 2Q07. The decrease was primarily driven by label and reimbursement changes in the U.S. for all erythropoiesis-stimulating agents. First-generation EPO drug Epogen had 3Q07 sales of $602M, off 5% from $633M in the same period last year and down 4% from $624M in 2Q07. AMGN said the decrease was due to a decline in dose per treatment and increased discounts. Vectibix also posted a sequential decline. The anti-EGFR antibody for colorectal cancer was launched last October and posted 3Q07 sales of $41M, down 9% from $45M in 2Q07. AMGN said the sales continue to be hampered by the negative Phase IIIb PACCE data released in March (see BioCentury, March 26, 2007). Sales of neutropenia products Neupogen and Neulasta were $1.1B, up 10% from $998M in 3Q06.3Q07 sales of Enbrel, which is marketed for rheumatoid arthritis (RA) and other inflammatory indications, were up 16% to $821M in North America. Wyeth (WYE) has exclusive rights to Enbrel outside North America. AMGN reiterated FY07 adjusted EPS guidance of $4.13-$4.23 (see "Trial doesn't Fix Tribulations," A8).
Applied Bio (ABI) (A) $0.31 $0.32 Beat by $0.01 10% $36.10 $0.78 2% $142.7 $6,605.3

Read the full 1751 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >